(BTSG) BrightSpring Health - Overview
Sector: HealthcareIndustry: Health Information Services | Exchange NASDAQ (USA) | Currency USD | Market Cap: 7.916m | Total Return 129.9% in 12m
Stock: Home Health, Pharmacy, Therapy, Behavioral
Total Rating 63
Risk 71
Buy Signal 0.70
| Risk 5d forecast | |
|---|---|
| Volatility | 46.0% |
| Relative Tail Risk | -5.98% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.00 |
| Alpha | 113.40 |
| Character TTM | |
|---|---|
| Beta | 1.348 |
| Beta Downside | 1.746 |
| Drawdowns 3y | |
|---|---|
| Max DD | 35.56% |
| CAGR/Max DD | 2.44 |
EPS (Earnings per Share)
Revenue
Risks
Fundamental:
P/E ratio: 85.8542
Description: BTSG BrightSpring Health March 04, 2026
BrightSpring Health Services, Inc. (BTSG) delivers home and community-based healthcare. This model addresses the growing preference for care outside traditional institutional settings, often driven by an aging population and advancements in home healthcare technology.
The company operates in two segments: Pharmacy Solutions and Provider Services. Pharmacy services include infused, injectable, and oral medications. Provider services encompass clinical home health care, rehabilitation (physical, speech, occupational therapy), and applied behavioral analysis. These services cater to Medicare, Medicaid, and commercially insured populations, reflecting the diverse funding landscape within the healthcare sector.
Founded in 1974 and headquartered in Louisville, Kentucky, BrightSpring Health Services, Inc. was formerly known as Phoenix Parent Holdings Inc. Further research on ValueRay can provide deeper insights into the companys financial performance and market position.
Headlines to watch out for
- Medicaid and Medicare reimbursement rates impact revenue
- Home health services demand drives growth
- Pharmacy solutions segment contributes to revenue
- Regulatory changes in healthcare sector pose risk
- Labor costs for skilled healthcare professionals affect profitability
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 190.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 8.61 > 1.0 |
| NWC/Revenue: 8.09% < 20% (prev 4.35%; Δ 3.74% < -1%) |
| CFO/TA 0.08 > 3% & CFO 490.2m > Net Income 190.7m |
| Net Debt (2.75b) to EBITDA (459.5m): 5.99 < 3 |
| Current Ratio: 1.57 > 1.5 & < 3 |
| Outstanding Shares: last quarter (219.8m) vs 12m ago 3.10% < -2% |
| Gross Margin: 11.76% > 18% (prev 0.13%; Δ 1.16k% > 0.5%) |
| Asset Turnover: 209.3% > 50% (prev 180.3%; Δ 28.98% > 0%) |
| Interest Coverage Ratio: 1.88 > 6 (EBITDA TTM 459.5m / Interest Expense TTM 157.3m) |
Altman Z'' 1.33
| A: 0.16 (Total Current Assets 2.89b - Total Current Liabilities 1.85b) / Total Assets 6.41b |
| B: -0.01 (Retained Earnings -74.6m / Total Assets 6.41b) |
| C: 0.05 (EBIT TTM 295.3m / Avg Total Assets 6.17b) |
| D: -0.02 (Book Value of Equity -79.4m / Total Liabilities 4.53b) |
| Altman-Z'' Score: 1.33 = BB |
Beneish M -3.14
| DSRI: 0.71 (Receivables 989.7m/1.15b, Revenue 12.91b/10.68b) |
| GMI: 1.14 (GM 11.76% / 13.43%) |
| AQI: 0.82 (AQ_t 0.49 / AQ_t-1 0.60) |
| SGI: 1.21 (Revenue 12.91b / 10.68b) |
| TATA: -0.05 (NI 190.7m - CFO 490.2m) / TA 6.41b) |
| Beneish M-Score: -3.14 (Cap -4..+1) = AA |
What is the price of BTSG shares?
As of March 28, 2026, the stock is trading at USD 42.33 with a total of 2,193,072 shares traded.
Over the past week, the price has changed by +2.72%, over one month by +2.17%, over three months by +11.87% and over the past year by +129.93%.
Over the past week, the price has changed by +2.72%, over one month by +2.17%, over three months by +11.87% and over the past year by +129.93%.
Is BTSG a buy, sell or hold?
BrightSpring Health has received a consensus analysts rating of 4.67.
Therefore, it is recommended to buy BTSG.
- StrongBuy: 9
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BTSG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 52.6 | 24.3% |
| Analysts Target Price | 52.6 | 24.3% |
BTSG Fundamental Data Overview March 23, 2026
P/E Trailing = 85.8542
P/E Forward = 40.6504
P/S = 0.6131
P/B = 4.2226
Revenue TTM = 12.91b USD
EBIT TTM = 295.3m USD
EBITDA TTM = 459.5m USD
Long Term Debt = 2.46b USD (from longTermDebt, last quarter)
Short Term Debt = 102.1m USD (from shortTermDebt, last quarter)
Debt = 2.84b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.75b USD (from netDebt column, last quarter)
Enterprise Value = 10.67b USD (7.92b + Debt 2.84b - CCE 88.4m)
Interest Coverage Ratio = 1.88 (Ebit TTM 295.3m / Interest Expense TTM 157.3m)
EV/FCF = 21.77x (Enterprise Value 10.67b / FCF TTM 490.2m)
FCF Yield = 4.59% (FCF TTM 490.2m / Enterprise Value 10.67b)
FCF Margin = 3.80% (FCF TTM 490.2m / Revenue TTM 12.91b)
Net Margin = 1.48% (Net Income TTM 190.7m / Revenue TTM 12.91b)
Gross Margin = 11.76% ((Revenue TTM 12.91b - Cost of Revenue TTM 11.39b) / Revenue TTM)
Gross Margin QoQ = 11.62% (prev 11.76%)
Tobins Q-Ratio = 1.66 (Enterprise Value 10.67b / Total Assets 6.41b)
Interest Expense / Debt = 1.36% (Interest Expense 38.5m / Debt 2.84b)
Taxrate = 28.78% (20.0m / 69.6m)
NOPAT = 210.3m (EBIT 295.3m * (1 - 28.78%))
Current Ratio = 1.57 (Total Current Assets 2.89b / Total Current Liabilities 1.85b)
Debt / Equity = 1.52 (Debt 2.84b / totalStockholderEquity, last quarter 1.88b)
Debt / EBITDA = 5.99 (Net Debt 2.75b / EBITDA 459.5m)
Debt / FCF = 5.62 (Net Debt 2.75b / FCF TTM 490.2m)
Total Stockholder Equity = 1.78b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.09% (Net Income 190.7m / Total Assets 6.41b)
RoE = 10.71% (Net Income TTM 190.7m / Total Stockholder Equity 1.78b)
RoCE = 6.97% (EBIT 295.3m / Capital Employed (Equity 1.78b + L.T.Debt 2.46b))
RoIC = 4.89% (NOPAT 210.3m / Invested Capital 4.30b)
WACC = 8.15% (E(7.92b)/V(10.76b) * Re(10.73%) + D(2.84b)/V(10.76b) * Rd(1.36%) * (1-Tc(0.29)))
Discount Rate = 10.73% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.30%
[DCF] Terminal Value 70.00% ; FCFF base≈490.2m ; Y1≈321.8m ; Y5≈147.2m
[DCF] Fair Price = 0.46 (EV 2.84b - Net Debt 2.75b = Equity 87.8m / Shares 192.1m; r=8.15% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 66.50 | EPS CAGR: 53.53% | SUE: 1.16 | # QB: 1
Revenue Correlation: 98.15 | Revenue CAGR: 22.68% | SUE: 1.30 | # QB: 4
EPS next Quarter (2026-06-30): EPS=0.36 | Chg7d=+0.001 | Chg30d=+0.072 | Revisions Net=+8 | Analysts=14
EPS current Year (2026-12-31): EPS=1.55 | Chg7d=+0.022 | Chg30d=+0.218 | Revisions Net=+12 | Growth EPS=+55.3% | Growth Revenue=+15.0%
EPS next Year (2027-12-31): EPS=1.94 | Chg7d=+0.045 | Chg30d=+0.295 | Revisions Net=+10 | Growth EPS=+25.2% | Growth Revenue=+12.6%
[Analyst] Revisions Ratio: +1.00 (8 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 9.6% (Discount Rate 10.7% - Earnings Yield 1.2%)
[Growth] Growth Spread = +5.3% (Analyst 14.8% - Implied 9.6%)
P/E Forward = 40.6504
P/S = 0.6131
P/B = 4.2226
Revenue TTM = 12.91b USD
EBIT TTM = 295.3m USD
EBITDA TTM = 459.5m USD
Long Term Debt = 2.46b USD (from longTermDebt, last quarter)
Short Term Debt = 102.1m USD (from shortTermDebt, last quarter)
Debt = 2.84b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.75b USD (from netDebt column, last quarter)
Enterprise Value = 10.67b USD (7.92b + Debt 2.84b - CCE 88.4m)
Interest Coverage Ratio = 1.88 (Ebit TTM 295.3m / Interest Expense TTM 157.3m)
EV/FCF = 21.77x (Enterprise Value 10.67b / FCF TTM 490.2m)
FCF Yield = 4.59% (FCF TTM 490.2m / Enterprise Value 10.67b)
FCF Margin = 3.80% (FCF TTM 490.2m / Revenue TTM 12.91b)
Net Margin = 1.48% (Net Income TTM 190.7m / Revenue TTM 12.91b)
Gross Margin = 11.76% ((Revenue TTM 12.91b - Cost of Revenue TTM 11.39b) / Revenue TTM)
Gross Margin QoQ = 11.62% (prev 11.76%)
Tobins Q-Ratio = 1.66 (Enterprise Value 10.67b / Total Assets 6.41b)
Interest Expense / Debt = 1.36% (Interest Expense 38.5m / Debt 2.84b)
Taxrate = 28.78% (20.0m / 69.6m)
NOPAT = 210.3m (EBIT 295.3m * (1 - 28.78%))
Current Ratio = 1.57 (Total Current Assets 2.89b / Total Current Liabilities 1.85b)
Debt / Equity = 1.52 (Debt 2.84b / totalStockholderEquity, last quarter 1.88b)
Debt / EBITDA = 5.99 (Net Debt 2.75b / EBITDA 459.5m)
Debt / FCF = 5.62 (Net Debt 2.75b / FCF TTM 490.2m)
Total Stockholder Equity = 1.78b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.09% (Net Income 190.7m / Total Assets 6.41b)
RoE = 10.71% (Net Income TTM 190.7m / Total Stockholder Equity 1.78b)
RoCE = 6.97% (EBIT 295.3m / Capital Employed (Equity 1.78b + L.T.Debt 2.46b))
RoIC = 4.89% (NOPAT 210.3m / Invested Capital 4.30b)
WACC = 8.15% (E(7.92b)/V(10.76b) * Re(10.73%) + D(2.84b)/V(10.76b) * Rd(1.36%) * (1-Tc(0.29)))
Discount Rate = 10.73% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.30%
[DCF] Terminal Value 70.00% ; FCFF base≈490.2m ; Y1≈321.8m ; Y5≈147.2m
[DCF] Fair Price = 0.46 (EV 2.84b - Net Debt 2.75b = Equity 87.8m / Shares 192.1m; r=8.15% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 66.50 | EPS CAGR: 53.53% | SUE: 1.16 | # QB: 1
Revenue Correlation: 98.15 | Revenue CAGR: 22.68% | SUE: 1.30 | # QB: 4
EPS next Quarter (2026-06-30): EPS=0.36 | Chg7d=+0.001 | Chg30d=+0.072 | Revisions Net=+8 | Analysts=14
EPS current Year (2026-12-31): EPS=1.55 | Chg7d=+0.022 | Chg30d=+0.218 | Revisions Net=+12 | Growth EPS=+55.3% | Growth Revenue=+15.0%
EPS next Year (2027-12-31): EPS=1.94 | Chg7d=+0.045 | Chg30d=+0.295 | Revisions Net=+10 | Growth EPS=+25.2% | Growth Revenue=+12.6%
[Analyst] Revisions Ratio: +1.00 (8 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 9.6% (Discount Rate 10.7% - Earnings Yield 1.2%)
[Growth] Growth Spread = +5.3% (Analyst 14.8% - Implied 9.6%)